Ignite Creation Date:
2025-12-24 @ 11:09 PM
Ignite Modification Date:
2026-01-02 @ 3:32 AM
Study NCT ID:
NCT05847569
Status:
RECRUITING
Last Update Posted:
2025-06-17
First Post:
2023-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Sponsor:
Mayo Clinic
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-04
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-05-29
Completion Date Type:
ESTIMATED
First Submit Date:
2023-04-27
First Submit QC Date:
None
Study First Post Date:
2023-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-13
Last Update Post Date:
2025-06-17
Last Update Post Date Type:
ACTUAL